Intravitreal Triamcinolone Acetonide for Choroidal Granuloma in Sarcoidosis - 18/08/11
: FRCS, Etrian Lim, MBBS, David T.L. Liu, MRCS, Ricky W.K. Law : FRCS, Dennis S.C. Lam, MD : FRCOphth
Inquiries to Prof. Wai-Man Chan, MRCP, FRCS, Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong, 3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong; Fax: (852) 2648-2943;Résumé |
Purpose |
To report the clinical course of intravitreal triamcinolone acetonide on choroidal granuloma secondary to sarcoidosis that was refractory to systemic prednisolone
Design |
Interventional case report.
Methods |
A 29-year-old Chinese man with sarcoidosis presented with isolated posterior segment involvement in his left eye as retinal periphlebitis, retinal granulomas, and choroidal granuloma. Retinal periphlebitis and retinal granulomas responded well to oral corticosteroid but not the choroidal granuloma. It gradually grew in size and caused a drop in left-eye vision to 20/70. Intravitreal triamcinolone acetonide (4 mg) was injected three times in total.
Results |
The choroidal mass began to shrink in size after the second injection and completely regressed after the third. The choroidal granuloma became a scar, with no angiographic leakage. The patient’s visual acuity improved and remained stable at 20/40 at the last follow-up, 6 months after the last injection.
Conclusions |
Given the encouraging results, further study on intravitreal triamcinolone acetonide for macular and peripapillary choroidal granulomas secondary to systemic sarcoidosis is warranted.
Le texte complet de cet article est disponible en PDF.Plan
Vol 139 - N° 6
P. 1116-1118 - juin 2005 Retour au numéro
Article précédent
- Linezolid-induced Optic Neuropathy
- Tomohiro Saijo, Keiko Hayashi, Hideyuki Yamada, Masato Wakakura
- Different Mutations in Carbohydrate Sulfotransferase 6 (CHST6) Gene Cause Macular Corneal Dystrophy Types I and II in a Single Sibship
- Ning-Pu Liu, Wenjun Bao, Clayton F. Smith, Jeffery M. Vance, Gordon K. Klintworth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?